Journal of Biotechnology & Biomaterials
Open Access

Abstract

Embolisation bead prototypes possessing significantly higher compression stiffness than commercially available products were compared in vitro in a flowing glass-plate model to assess their penetration potential and bead size, not stiffness, was shown to be the influential factor. The comparative arterial distribution of prototypes in the 40-90 �¼m and 70-150 �¼m size range, together with commercially available products (Embozene(TM)) was performed in a rabbit renal arterial embolisation model. Kidneys were embolised in 9 rabbits with beads of a particular size. Following embolisation of the second kidney with the comparator product, the animals were sacrificed and histologic evaluation performed. Three radial tissue slices, evenly distributed from the upper to lower poles were sectioned from each kidney and stained with haematein-eosin-saffron. The pathology evaluation assessed. The arterial distribution pattern in histology according to a division of the kidney in 5 zones of diminishing vessel diameter; Diameter of the occluded vessels; Number of beads present in occluded vessel sections; and in vivo deformation of the beads. The model could clearly differentiate between the distributions patterns of beads of different sizes. Measurements of the diameter of occluded vessels highlighted that in all cases, the smaller bead sizes occluded more distally than larger beads. In addition, this model allowed for a comparison between beads of different stiffness but similar diameter and supported the in vitro data from the glass plate model that size and not stiffness was the biggest influence on depth of penetration and distribution.

Biography

Hugh Kilpatrick is a Senior Manager within the Non-Clinical Development department at BTG. Within this role he oversees the planning and management of nonclinical and bio-analytical studies to assess the safety and efficacy of medical devices, which are then used to support the regulatory submission. He has over 15 years experience as a non-clinical study manager of GLP toxicology studies for the registration of pharmaceutical, veterinary, agrochemical and industrial materials.

Email: hugh.kilpatrick@btgplc.com